Cargando…
Stimuli-Responsive Gene Delivery Nanocarriers for Cancer Therapy
Gene therapy provides a promising approach in treating cancers with high efficacy and selectivity and few adverse effects. Currently, the development of functional vectors with safety and effectiveness is the intense focus for improving the delivery of nucleic acid drugs for gene therapy. For this p...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Nature Singapore
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9908819/ https://www.ncbi.nlm.nih.gov/pubmed/36752939 http://dx.doi.org/10.1007/s40820-023-01018-4 |
_version_ | 1784884441515032576 |
---|---|
author | Zhang, Qingfei Kuang, Gaizhen Li, Wenzhao Wang, Jinglin Ren, Haozhen Zhao, Yuanjin |
author_facet | Zhang, Qingfei Kuang, Gaizhen Li, Wenzhao Wang, Jinglin Ren, Haozhen Zhao, Yuanjin |
author_sort | Zhang, Qingfei |
collection | PubMed |
description | Gene therapy provides a promising approach in treating cancers with high efficacy and selectivity and few adverse effects. Currently, the development of functional vectors with safety and effectiveness is the intense focus for improving the delivery of nucleic acid drugs for gene therapy. For this purpose, stimuli-responsive nanocarriers displayed strong potential in improving the overall efficiencies of gene therapy and reducing adverse effects via effective protection, prolonged blood circulation, specific tumor accumulation, and controlled release profile of nucleic acid drugs. Besides, synergistic therapy could be achieved when combined with other therapeutic regimens. This review summarizes recent advances in various stimuli-responsive nanocarriers for gene delivery. Particularly, the nanocarriers responding to endogenous stimuli including pH, reactive oxygen species, glutathione, and enzyme, etc., and exogenous stimuli including light, thermo, ultrasound, magnetic field, etc., are introduced. Finally, the future challenges and prospects of stimuli-responsive gene delivery nanocarriers toward potential clinical translation are well discussed. The major objective of this review is to present the biomedical potential of stimuli-responsive gene delivery nanocarriers for cancer therapy and provide guidance for developing novel nanoplatforms that are clinically applicable. [Image: see text] |
format | Online Article Text |
id | pubmed-9908819 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer Nature Singapore |
record_format | MEDLINE/PubMed |
spelling | pubmed-99088192023-02-10 Stimuli-Responsive Gene Delivery Nanocarriers for Cancer Therapy Zhang, Qingfei Kuang, Gaizhen Li, Wenzhao Wang, Jinglin Ren, Haozhen Zhao, Yuanjin Nanomicro Lett Review Gene therapy provides a promising approach in treating cancers with high efficacy and selectivity and few adverse effects. Currently, the development of functional vectors with safety and effectiveness is the intense focus for improving the delivery of nucleic acid drugs for gene therapy. For this purpose, stimuli-responsive nanocarriers displayed strong potential in improving the overall efficiencies of gene therapy and reducing adverse effects via effective protection, prolonged blood circulation, specific tumor accumulation, and controlled release profile of nucleic acid drugs. Besides, synergistic therapy could be achieved when combined with other therapeutic regimens. This review summarizes recent advances in various stimuli-responsive nanocarriers for gene delivery. Particularly, the nanocarriers responding to endogenous stimuli including pH, reactive oxygen species, glutathione, and enzyme, etc., and exogenous stimuli including light, thermo, ultrasound, magnetic field, etc., are introduced. Finally, the future challenges and prospects of stimuli-responsive gene delivery nanocarriers toward potential clinical translation are well discussed. The major objective of this review is to present the biomedical potential of stimuli-responsive gene delivery nanocarriers for cancer therapy and provide guidance for developing novel nanoplatforms that are clinically applicable. [Image: see text] Springer Nature Singapore 2023-02-08 /pmc/articles/PMC9908819/ /pubmed/36752939 http://dx.doi.org/10.1007/s40820-023-01018-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Review Zhang, Qingfei Kuang, Gaizhen Li, Wenzhao Wang, Jinglin Ren, Haozhen Zhao, Yuanjin Stimuli-Responsive Gene Delivery Nanocarriers for Cancer Therapy |
title | Stimuli-Responsive Gene Delivery Nanocarriers for Cancer Therapy |
title_full | Stimuli-Responsive Gene Delivery Nanocarriers for Cancer Therapy |
title_fullStr | Stimuli-Responsive Gene Delivery Nanocarriers for Cancer Therapy |
title_full_unstemmed | Stimuli-Responsive Gene Delivery Nanocarriers for Cancer Therapy |
title_short | Stimuli-Responsive Gene Delivery Nanocarriers for Cancer Therapy |
title_sort | stimuli-responsive gene delivery nanocarriers for cancer therapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9908819/ https://www.ncbi.nlm.nih.gov/pubmed/36752939 http://dx.doi.org/10.1007/s40820-023-01018-4 |
work_keys_str_mv | AT zhangqingfei stimuliresponsivegenedeliverynanocarriersforcancertherapy AT kuanggaizhen stimuliresponsivegenedeliverynanocarriersforcancertherapy AT liwenzhao stimuliresponsivegenedeliverynanocarriersforcancertherapy AT wangjinglin stimuliresponsivegenedeliverynanocarriersforcancertherapy AT renhaozhen stimuliresponsivegenedeliverynanocarriersforcancertherapy AT zhaoyuanjin stimuliresponsivegenedeliverynanocarriersforcancertherapy |